{
    "info": {
        "nct_id": "NCT04586231",
        "official_title": "An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy",
        "inclusion_criteria": "* Unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC).\n* Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy as either first or second-line treatment for locally advanced/metastatic RCC or as adjuvant treatment or neoadjuvant/adjuvant with progression on or within 6 months of last dose.\n* Measurable disease per RECIST 1.1 criteria as assessed by local study investigator.\n* Karnofsky performance status (KPS) score of at least 70% assessed within 10 days before randomization.\n* Received no more than 2 prior systemic regimens including: one anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimens with progression on or within 6 months from the last dose of that regimen OR one or 2 regimens for locoregional/advanced disease\n* Received only 1 prior antiPD-1/L1 therapy for adjuvant, neoadjuvant/adjuvant or locally advanced/metastatic RCC.\n* A male participant is eligible to participate if he is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 7 days after the last dose of belzutifan or lenvatinib in the belzutifan+lenvatinib arm, whichever occurs last, and 23 days after the last dose of cabozantinib.\n* A female participant is eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention in the belzutifan+ lenvatinib arm, or 120 days after the last dose of study intervention in the cabozantinib arm.\n* Adequately controlled blood pressure.\n* Adequate organ function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* A pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen.\n* Known additional malignancy that is progressing or has required active treatment within the past 3 years except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy.\n* Known central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Clinically significant cardiac disease within 6 months of first dose of study intervention.\n* Prolongation of QTc interval to >480 ms.\n* Symptomatic pleural effusion (e.g.,cough, dyspnea, pleuritic chest pain) that is not clinically stable.\n* Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula.\n* Moderate to severe hepatic impairment.\n* History of significant bleeding within 3 months before randomization.\n* History of solid organ transplantation.\n* Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.\n* Unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption).\n* Known hypersensitivity or allergy to the active pharmaceutical ingredients or any component of the study intervention formulations.\n* Received colony-stimulating factors [eg, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant erythropoietin (EPO)] within 28 days before randomization.\n* Prior treatment with belzutifan or another hypoxia-inducible factor (HIF)-2α inhibitor.\n* Prior treatment with lenvatinib.\n* Prior treatment with cabozantinib.\n* Currently participating in a study of an investigational agent or using an investigational device.\n* Active infection requiring systemic therapy.\n* History of human immunodeficiency virus (HIV) infection.\n* History of hepatitis B or known active hepatitis C infection.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Adequately controlled blood pressure.",
            "criterions": [
                {
                    "exact_snippets": "Adequately controlled blood pressure",
                    "criterion": "blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "adequately controlled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function.",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Karnofsky performance status (KPS) score of at least 70% assessed within 10 days before randomization.",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky performance status (KPS) score of at least 70%",
                    "criterion": "Karnofsky performance status (KPS) score",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "assessment recency",
                            "expected_value": "within 10 days before randomization"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received only 1 prior antiPD-1/L1 therapy for adjuvant, neoadjuvant/adjuvant or locally advanced/metastatic RCC.",
            "criterions": [
                {
                    "exact_snippets": "Received only 1 prior antiPD-1/L1 therapy",
                    "criterion": "prior antiPD-1/L1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for adjuvant, neoadjuvant/adjuvant or locally advanced/metastatic RCC",
                    "criterion": "indication for prior antiPD-1/L1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": [
                                "adjuvant",
                                "neoadjuvant/adjuvant",
                                "locally advanced/metastatic RCC"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease per RECIST 1.1 criteria as assessed by local study investigator.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease per RECIST 1.1 criteria",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment standard",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "as assessed by local study investigator",
                    "criterion": "assessment by local study investigator",
                    "requirements": [
                        {
                            "requirement_type": "assessor",
                            "expected_value": "local study investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC).",
            "criterions": [
                {
                    "exact_snippets": "Unresectable",
                    "criterion": "tumor resectability",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "clear cell renal cell carcinoma (RCC)",
                    "criterion": "histology",
                    "requirements": [
                        {
                            "requirement_type": "histological type",
                            "expected_value": "clear cell renal cell carcinoma"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A female participant is eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention in the belzutifan+ lenvatinib arm, or 120 days after the last dose of study intervention in the cabozantinib arm.",
            "criterions": [
                {
                    "exact_snippets": "female participant",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "not pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Not a woman of childbearing potential (WOCBP)",
                    "criterion": "woman of childbearing potential status",
                    "requirements": [
                        {
                            "requirement_type": "WOCBP",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention in the belzutifan+ lenvatinib arm",
                    "criterion": "contraceptive use (belzutifan+lenvatinib arm)",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration after last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least ... 120 days after the last dose of study intervention in the cabozantinib arm",
                    "criterion": "contraceptive use (cabozantinib arm)",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration after last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 120,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received no more than 2 prior systemic regimens including: one anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimens with progression on or within 6 months from the last dose of that regimen OR one or 2 regimens for locoregional/advanced disease",
            "criterions": [
                {
                    "exact_snippets": "Received no more than 2 prior systemic regimens",
                    "criterion": "number of prior systemic regimens",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "regimens"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "one anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimens",
                    "criterion": "prior anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimen",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "progression on or within 6 months from the last dose of that regimen",
                    "criterion": "progression after anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimen",
                    "requirements": [
                        {
                            "requirement_type": "progression_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months from last dose"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "one or 2 regimens for locoregional/advanced disease",
                    "criterion": "prior regimens for locoregional/advanced disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "regimen"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "regimens"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A male participant is eligible to participate if he is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 7 days after the last dose of belzutifan or lenvatinib in the belzutifan+lenvatinib arm, whichever occurs last, and 23 days after the last dose of cabozantinib.",
            "criterions": [
                {
                    "exact_snippets": "male participant",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 7 days after the last dose of belzutifan or lenvatinib in the belzutifan+lenvatinib arm, whichever occurs last, and 23 days after the last dose of cabozantinib",
                    "criterion": "contraception or abstinence during and after intervention",
                    "requirements": [
                        {
                            "requirement_type": "behavior",
                            "expected_value": [
                                "abstinence from heterosexual intercourse",
                                "use of contraception"
                            ]
                        },
                        {
                            "requirement_type": "duration after last dose (belzutifan or lenvatinib, belzutifan+lenvatinib arm)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "duration after last dose (cabozantinib)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 23,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy as either first or second-line treatment for locally advanced/metastatic RCC or as adjuvant treatment or neoadjuvant/adjuvant with progression on or within 6 months of last dose.",
            "criterions": [
                {
                    "exact_snippets": "Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy",
                    "criterion": "disease progression after PD-1/L1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "on or after PD-1/L1 therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "as either first or second-line treatment for locally advanced/metastatic RCC",
                    "criterion": "PD-1/L1 therapy line and indication",
                    "requirements": [
                        {
                            "requirement_type": "line of therapy",
                            "expected_value": [
                                "first-line",
                                "second-line"
                            ]
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "locally advanced/metastatic RCC"
                        }
                    ]
                },
                {
                    "exact_snippets": "as adjuvant treatment or neoadjuvant/adjuvant with progression on or within 6 months of last dose",
                    "criterion": "PD-1/L1 therapy as adjuvant or neoadjuvant/adjuvant with progression timing",
                    "requirements": [
                        {
                            "requirement_type": "treatment setting",
                            "expected_value": [
                                "adjuvant",
                                "neoadjuvant/adjuvant"
                            ]
                        },
                        {
                            "requirement_type": "progression timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months after last dose"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.",
            "criterions": [
                {
                    "exact_snippets": "Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.",
                    "criterion": "psychiatric disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "interference with cooperation with the requirements of the study",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.",
                    "criterion": "substance abuse disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "interference with cooperation with the requirements of the study",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant cardiac disease within 6 months of first dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiac disease within 6 months of first dose of study intervention.",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since occurrence",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prolongation of QTc interval to >480 ms.",
            "criterions": [
                {
                    "exact_snippets": "Prolongation of QTc interval to >480 ms",
                    "criterion": "QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "ms"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of solid organ transplantation.",
            "criterions": [
                {
                    "exact_snippets": "History of solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen.",
            "criterions": [
                {
                    "exact_snippets": "A pulse oximeter reading <92% at rest",
                    "criterion": "pulse oximeter reading at rest",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 92,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "requires intermittent supplemental oxygen",
                    "criterion": "intermittent supplemental oxygen requirement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requires chronic supplemental oxygen",
                    "criterion": "chronic supplemental oxygen requirement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known additional malignancy that is progressing or has required active treatment within the past 3 years except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy.",
            "criterions": [
                {
                    "exact_snippets": "Known additional malignancy that is progressing or has required active treatment within the past 3 years",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "progressing",
                                "has required active treatment within the past 3 years"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy",
                    "criterion": "basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ)",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": "have undergone potentially curative therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity or allergy to the active pharmaceutical ingredients or any component of the study intervention formulations.",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity or allergy to the active pharmaceutical ingredients",
                    "criterion": "hypersensitivity or allergy to active pharmaceutical ingredients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity or allergy to ... any component of the study intervention formulations",
                    "criterion": "hypersensitivity or allergy to any component of the study intervention formulations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with lenvatinib.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with lenvatinib",
                    "criterion": "lenvatinib treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of hepatitis B or known active hepatitis C infection.",
            "criterions": [
                {
                    "exact_snippets": "History of hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known active hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of significant bleeding within 3 months before randomization.",
            "criterions": [
                {
                    "exact_snippets": "History of significant bleeding within 3 months before randomization.",
                    "criterion": "significant bleeding",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months before randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection requiring systemic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring systemic therapy",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of human immunodeficiency virus (HIV) infection.",
            "criterions": [
                {
                    "exact_snippets": "History of human immunodeficiency virus (HIV) infection.",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received colony-stimulating factors [eg, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant erythropoietin (EPO)] within 28 days before randomization.",
            "criterions": [
                {
                    "exact_snippets": "Received colony-stimulating factors [eg, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant erythropoietin (EPO)] within 28 days before randomization.",
                    "criterion": "colony-stimulating factor administration",
                    "requirements": [
                        {
                            "requirement_type": "administration_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days before randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Moderate to severe hepatic impairment.",
            "criterions": [
                {
                    "exact_snippets": "Moderate to severe hepatic impairment",
                    "criterion": "hepatic impairment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula.",
            "criterions": [
                {
                    "exact_snippets": "Pre-existing ≥Grade 3 gastrointestinal ... fistula",
                    "criterion": "gastrointestinal fistula",
                    "requirements": [
                        {
                            "requirement_type": "pre-existence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Pre-existing ≥Grade 3 ... nongastrointestinal fistula",
                    "criterion": "nongastrointestinal fistula",
                    "requirements": [
                        {
                            "requirement_type": "pre-existence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with belzutifan or another hypoxia-inducible factor (HIF)-2α inhibitor.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with belzutifan",
                    "criterion": "prior treatment with belzutifan",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... another hypoxia-inducible factor (HIF)-2α inhibitor",
                    "criterion": "prior treatment with HIF-2α inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known central nervous system (CNS) metastases and/or carcinomatous meningitis.",
            "criterions": [
                {
                    "exact_snippets": "Known central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "knowledge_status",
                            "expected_value": "known"
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption).",
            "criterions": [
                {
                    "exact_snippets": "Unable to swallow orally administered medication",
                    "criterion": "ability to swallow orally administered medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "gastrointestinal disorder affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption)",
                    "criterion": "gastrointestinal disorder affecting absorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with cabozantinib.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with cabozantinib",
                    "criterion": "cabozantinib treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic pleural effusion (e.g.,cough, dyspnea, pleuritic chest pain) that is not clinically stable.",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic pleural effusion",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not clinically stable",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "clinical stability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently participating in a study of an investigational agent or using an investigational device.",
            "criterions": [
                {
                    "exact_snippets": "Currently participating in a study of an investigational agent",
                    "criterion": "participation in a study of an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "using an investigational device",
                    "criterion": "use of an investigational device",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}